Yinfenidone
- Generic Name
- Yinfenidone
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Indication
用于治疗特发性肺纤维化（IPF）以及进行性纤维化性间质性肺疾病。
- Associated Conditions
- -
- Associated Therapies
- -
To Evaluate Drug-drug Interactions Between HEC585 and Pirfenidone or Nintedanib in Healthy Volunteers
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2022-05-19
- Last Posted Date
- 2022-05-19
- Lead Sponsor
- Sunshine Lake Pharma Co., Ltd.
- Target Recruit Count
- 33
- Registration Number
- NCT05383131
- Locations
- 🇨🇳
Shanghai Xuhui Central Hospital, Shanghai, China
Phase ll Study of HEC585 in Patients With IPF
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2021-09-29
- Last Posted Date
- 2023-08-18
- Lead Sponsor
- Sunshine Lake Pharma Co., Ltd.
- Target Recruit Count
- 270
- Registration Number
- NCT05060822
- Locations
- 🇨🇳
China-Japan Friendship Hospital, Beijing, Beijing, China
Single and Multiple Dose Safety, Tolerability, PK and Food Effect Study of HEC585 in Healthy Male and Female Subjects
- First Posted Date
- 2020-08-13
- Last Posted Date
- 2022-03-15
- Lead Sponsor
- Sunshine Lake Pharma Co., Ltd.
- Target Recruit Count
- 72
- Registration Number
- NCT04512170
- Locations
- 🇨🇳
Shanghai Xuhui Central Hospital, Shanghai, China
The Safety, Tolerability and Pharmacokinetic Study of HEC585 in Healthy Male and Female Subjects
- First Posted Date
- 2017-03-27
- Last Posted Date
- 2020-07-27
- Lead Sponsor
- Sunshine Lake Pharma Co., Ltd.
- Target Recruit Count
- 136
- Registration Number
- NCT03092102
- Locations
- 🇺🇸
Covance Clinical Research Unit, Inc., Madison, Wisconsin, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath